News | Optical Coherence Tomography (OCT) | May 16, 2016

OCT Helps Predict Significant Side Branch Ostium Stenosis

Optical Coherence Tomography Bifurcation Study (ORBID) identified predictors in SCAI late-breaker

OCT, ORBID study

May 16, 2016 — In a new study using optical coherence tomography (OCT), an invasive laser imaging technique that provides high-resolution images, researchers found that maximum lipid arc and the presence of lipid plaque contralateral to the side branch (SB) ostium before stenting may contribute to significant side branch ostium stenosis (SBOS) after stenting. The results of the ORBID study were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting.

Stenting in the main vessel can result in significant SBOS, making it important for interventional cardiologists to be able to identify at-risk patients before they undergo percutaneous coronary intervention (PCI). Significant SBOS is defined as a blockage of 50 percent or more based on angiography. ORBID study researchers aimed to identify predictors of significant SBOS before a stent is introduced in the main vessel, using OCT, which is in the research-phase for this application. OCT is more accurate and provides higher resolution imaging than ultrasound, which is currently the most widely used method in clinical care.

“When inserting a stent into the main vessel of a patient, we have the option of also inserting a wire in the side branch in case SBOS occurs,” said Samin Sharma, M.D., FSCAI, an investigator of the study and director of clinical cardiology and intervention, dean of international clinical affiliations, and president of the Mount Sinai Heart Network, The Mount Sinai Hospital, N.Y. “In our study, OCT proved helpful in identifying predictors of SBOS prior to PCI, which may allow for avoiding inserting a wire in the side branch in select cases.”

The prospective single-center study analyzed 30 patients who did not have initial blockage in the SB ostium. Post-stenting significant SBOS was observed in 30 percent of patients. Affected patients were characterized by a higher prevalence of lipids in the blood (100 vs. 64 percent, p = 0.040) and spotty calcifications (60 vs. 0 percent, p = 0.005).

A multivariate logistic regression analysis identified maximal lipid arc (odds ratio [OR]: 1.014, p = 0.038) and the presence of lipid plaque contralateral to SB ostium (OR: 8.14, p = 0.046) before stenting as independent predictors of significant SBOS.
“This initial study indicates that OCT is a helpful tool in identifying predictors of significant SBOS in patients before they receive a stent,” Sharma said. “In the future, this imaging technology could be broadly introduced as a tool to identify at-risk patients, thereby giving interventional cardiologists more information before doing bifurcation stenting.”

Sharma reported no disclosures. The study was sponsored by Boston Scientific.

For more information: www. SCAI.org/SCAI2016 

 

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init